MedTrace Logo

Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

NCT05781906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-07-16

No results posted yet for this study

Summary

To evaluate the absorption, metabolism and excretion of HMPL-523 in healthy male Chinese subjects following multiple oral doses of HMPL-523 tablets followed by a single oral dose of \[14C\]HMPL-523 suspension

Conditions

  • Imumune Thrombocytopenia(ITP) Human Mass Balance

Interventions

DRUG

HMPL-523

D1-D7: HMPL-523 Tablet 300 mg QD

DRUG

150 µCi [14C]HMPL-523

D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Liyan Miao · offices director

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2023-06-01
Completion
2023-12-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05781906 on ClinicalTrials.gov